Sfoglia per AUTORE
BANNA GL
Collezione AOU Novara

  

Items : 6

Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis. in European urology oncology / Eur Urol Oncol. 2024 Apr;7(2):179-188. doi: 10.1016/j.euo.2023.07.013. Epub 2023 Aug 12.

2024
AOU Novara

Oing C; Plummer R; Greystoke A; Fornarini G; Bauckneht M; Cattrini C; Maniam A; Buti S; Banna GL; Rebuzzi SE; Messina C; Giunta EF; Signori A; Rescigno P;

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.

2022
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Russo A; Russano M; Tiseo M; Porzio G; Ficorella C; Addeo A; Friedlaender A; Banna GL; Passiglia F; Spinelli GP; Metro G; Migliorino MR; Zoratto F; Ricciardi S; Mansueto G; Pecci F; Di Marino P; Gori S; De Tursi M; Tuzi A; Della Gravara L; Rastelli F; Macerelli M; Gelibter A; Chiari R; Marchetti P; Antonuzzo L; Mazzoni F; Genova C; et alii...

Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ?50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. in Thoracic cancer / Thorac Cancer. 2022 Feb;13(3):483-488. doi: 10.1111/1759-7714.14256. Epub 2021 Dec 22.

2022
ASL Città di Torino
AOU Novara

Cortellini A; Addeo A; Pinato DJ; Porzio G; Ficorella C; Pensieri MV; Friedlaender A; Metro G; De Toma A; Cappuzzo F; Bertolini F; Rijavec E; Citarella F; Cantini L; Mansueto G; Gori S; Macerelli M; Chiari R; Rastelli F; Gelibter A; Mazzoni F; Catino A; Genova C; Morabito A; Grossi F; Berardi R; Bria E; Giusti R; Baldessari C; et alii...

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.

2021
AOU San Luigi di Orbassano
AO Ordine Mauriziano
AOU Novara

Russo A; Adamo V; Metro G; De Filippis M; Simona C; Natalizio S; Migliorino MR; Ricciardi S; Landi L; Minuti G; Buti S; Nigro O; Cantini L; Russano M; Citarella F; Bracarda S; Filetti M; Zoratto F; Mansueto G; De Tursi M; Gori S; Rocco D; Chiari R; Rastelli F; Gelibter A; Targato G; Signorelli D; De Toma A; Mazzoni F; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cannita K; Porzio G; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Russo A; Adamo V; Metro G; Olmetto E; Tabbò F; Migliorino MR; Ricciardi S; Landi L; Minuti G; Tuzi A; Bisonni R; Follador A; Siringo M; Gelibter A; Signorelli D; De Toma A; Garassino MC; Mazzoni F; Russano M; Citarella F; Filetti M; Zoratto F; Mansueto G; et alii...

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. in Journal for immunotherapy of cancer / J Immunother Cancer. 2021 Apr;9(4):e002421. doi: 10.1136/jitc-2021-002421.

2021
AOU San Luigi di Orbassano
ASL Città di Torino
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Russo A; Adamo V; Metro G; Bironzo P; Passiglia F; Migliorino MR; Ricciardi S; Landi L; Minuti G; Bordi P; Tuzi A; Cantini L; Russano M; Citarella F; Santini D; Filetti M; Zoratto F; Mansueto G; Di Marino P; Grassadonia A; Michele T; Inno A; Della Gravara L; Rocco D; Chiari R; Rastelli F; Macerelli M; Marchetti P; Siringo M; et alii...